50% off Premium Yearly

TSE:ZUH
This summary was created by AI, based on 1 opinions in the last 12 months.
BMO EqWt US Healthcare Hedged CAD (ZUH-T) stands out as an equal-weighted investment option that effectively mitigates the risks associated with concentration in mega-pharmaceutical companies. The focus on pharmaceuticals, biotechnology, and healthcare services positions it within a lower volatility sector that is beneficial for diversification, particularly in light of the current narrow leadership seen in broader market indexes. Experts note the defensive growth characteristics of this sector, underscored by steady demand and robust balance sheets, making it less sensitive to economic fluctuations. Additionally, the burgeoning innovation within healthcare driven by advancements in AI is positioned to provide significant long-term benefits. Overall, the outlook is positive, given the favorable valuations present in this market segment.
They use a covered call strategy to enhance the yield. Those who want exposure to healthcare space but want higher yield, it is a good option. If yield is not a concern for you, you're better off with ZUH.
Billy Kawasaki’s Insights - Picks from 5i Research. Healthcare is likely to be a strong performer in the next five years. Subsectors like medical devices, telemedicine and therapeutics should lead. A good ETF for US exposure. Unlock Premium - Try 5i Free
He does not own this one. They have an effective covered call strategy and has no issues with the fund at all. He prefers ZUH, where it is not impeded with calls being written.
60 names, equally weighted. Prefers names like JNJ, Bristol Myers, UNH, or Merck. His ETF strategy is VHT in US dollars, with more exposure to larger names. Healthcare will be choppy, but it's cheap. Demographics are in its favour.
BMO EqWt US HthCare Hedged CAD is a Canadian stock, trading under the symbol ZUH.TO (previously ZUH-T on Stockchase) on the Toronto Stock Exchange (ZUH-CT). It is usually referred to as TSX:ZUH or ZUH.TO
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on ZUH.TO (previously ZUH-T on Stockchase). 1 analyst recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is . Read the latest stock experts' ratings for BMO EqWt US HthCare Hedged CAD.
BMO EqWt US HthCare Hedged CAD was recommended as a Top Pick by Mike S. Newton, CIM FCSI on 2019-04-24. Read the latest stock experts ratings for BMO EqWt US HthCare Hedged CAD.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for BMO EqWt US HthCare Hedged CAD.
BMO EqWt US HthCare Hedged CAD is followed by 76 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-15, BMO EqWt US HthCare Hedged CAD (ZUH.TO) stock closed at a price of $68.66.
Equal weight avoids concentration in mega-pharma. Pharma, biotech, healthcare services. Lower volatility sector, so it helps diversify against the narrow leadership in the indexes right now. Defensive growth, steady demand in the area, strong balance sheets, low economic sensitivity. Good valuations.
Kicker is lots of healthcare innovation coming due to AI, and this will be a huge benefit.
Disclosure: Owns this for clients via the futures market. Though he may own similar exposure at times, he doesn't own the individual ETF. His team creates the exposure in a different way.